Get the Stockscreener App
4.2892
3.53%
0.0392
Cyclerion Therapeutics Inc stock is traded at $4.2892, with a volume of 131.04K.
It is up +3.53% in the last 24 hours and up +35.38% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$4.25
Open:
$4.36
24h Volume:
131.04K
Relative Volume:
0.03
Market Cap:
$11.52M
Revenue:
$556.00K
Net Income/Loss:
$-5.28M
P/E Ratio:
-2.0043
EPS:
-2.14
Net Cash Flow:
$-6.23M
1W Performance:
+12.24%
1M Performance:
+35.38%
6M Performance:
+45.80%
1Y Performance:
+57.14%
1-Day Range:
$4.19
$4.80
1-Week Range:
$3.93
$6.25
52-Week Range:
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
4.4145 | 11.52M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.19 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.89 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
3 US Penny Stocks With Market Caps Over $10M To Consider - Simply Wall St
Cyclerion Therapeutics Inc (NASDAQ: CYCN) Is The Number One Stock Currently Moving. - Stocks Register
Market Recap Check: Cyclerion Therapeutics Inc (CYCN)’s Negative Finish at 4.19, Up/Down -21.24 - The Dwinnex
Small Cap Stocks To ConsiderFebruary 02nd - MarketBeat
Cyclerion Therapeutics announces mixed shelf offering - MSN
Cyclerion Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Check out these key findings about Cyclerion Therapeutics Inc (CYCN) - SETE News
3 Penny Stocks to Watch Now, 2/4/25 - TipRanks
A company insider recently sold 357,880 shares of Cyclerion Therapeutics Inc [CYCN]. Should You also Consider to Sale? – Knox Daily - Knox Daily
Analyzing CYCN’s current quarter earnings projections - US Post News
Biotech Alert: Searches spiking for these stocks today - TipRanks
Top Gainers Today: Reborn Coffee (REBN) Leads with a 65% Surge, Cyclerion (CYCN) and Signing Day Sports (SGN) Follow – market - HPBL
Stock summary: Cyclerion Therapeutics surged by 41.01% over the past five days - Business Upturn
Stock market today: Signing Day Sports +62.89%, Cyclerion Therapeutics +57.43% among top gainers in early trading - Business Upturn
Top Premarket Gainers -January 31, 2025 at 07:32 am EST - Marketscreener.com
Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 3.5% – Time to Buy? - Defense World
Looking Into Cyclerion Therapeutics's Recent Short Interest - Benzinga
Extended Session Gains Propel Cyclerion (CYCN) Amid Revenue Progress - Stocks Telegraph
Cyclerion Therapeutics (NASDAQ: CYCN) Amends License Agreement with Akebia Therapeutics and Generates Revenues for GrowthOn December 17, 2024, Cyclerion Therapeutics, Inc. filed an 8-K SEC Filing which detailed significant developments in its b - Defense World
Cyclerion advances growth strategy with new agreements - Investing.com
Cyclerion Therapeutics Secures Funding and Expands CNS Focus - TipRanks
Cyclerion advances growth strategy with new agreements By Investing.com - Investing.com UK
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewswire
Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan
Head to Head Survey: Cyclerion Therapeutics (NASDAQ:CYCN) vs. scPharmaceuticals (NASDAQ:SCPH) - Defense World
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update - Defense World
3 US Penny Stocks With Market Caps Under $100M - Simply Wall St
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations - Investing.com Canada
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Stock market news: Cyclerion Therapeutics +280.50%, Cross Country Healthcare +62.01% among top gainers during mid day trading - Business Upturn
Stock market news: Relmada Therapeutics plunged by 75.54% while Cyclerion Therapeutics surged by 280.12% during mid day trading - Business Upturn
Stock market today: Cyclerion Therapeutics +343.79%, Cross Country Healthcare +63.04% among top gainers in early trading - Business Upturn
Stock market today: Relmada Therapeutics declined by 74.74% while Cyclerion Therapeutics saw surge of 392.22% in early trading - Business Upturn
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations By Investing.com - Investing.com South Africa
Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Benzinga
CYCN (Cyclerion Therapeutics) 3-Year EBITDA Growth Rate : 57.30% (As of Sep. 2024) - GuruFocus.com
CYCN (Cyclerion Therapeutics) GF Value Rank : 5 (As of Nov. 25, 2024) - GuruFocus.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cyclerion stock hits 52-week low at $1.55 amid market challenges - Investing.com Canada
Cyclerion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa
Cyclerion Therapeutics Inc (CYCN) Quarterly 10-Q Report - Quartzy
Cyclerion Therapeutics stock hits 52-week low at $1.75 By Investing.com - Investing.com South Africa
Cyclerion Therapeutics stock hits 52-week low at $1.75 - Investing.com India
Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader Magazine
Vascular Dementia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
cyclerion therapeutics, inc. Earnings dates - RTTNews
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 8.1% - Defense World
Analyzing Cyclerion Therapeutics (NASDAQ:CYCN) and Seelos Therapeutics (NASDAQ:SEEL) - Defense World
Cyclerion appoints Regina Graul as CEO and President - Investing.com
Regina Graul, Ph.D., Promoted to Chief Executive Officer - Morningstar
Cyclerion Therapeutics Promotes Regina Graul, Ph.D., to Chief Executive Officer - citybiz
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):